US Stock MarketDetailed Quotes
BCAX Bicara Therapeutics
- 19.195
- -0.975-4.83%
Close Nov 18 16:00 ET
1.04BMarket Cap-17561P/E (TTM)
21.190High18.730Low369.00KVolume19.740Open20.170Pre Close7.10MTurnover2.11%Turnover RatioLossP/E (Static)54.42MShares28.09052wk High2.05P/B335.91MFloat Cap18.33052wk Low--Dividend TTM17.50MShs Float28.090Historical High--Div YieldTTM12.20%Amplitude18.330Historical Low19.252Avg Price1Lot Size
Bicara Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | |||||
| Cash flow from continuing operating activities | -63.54%-17.22M | -42.25%-45.63M | -8.04M | -10.53M | -32.08M |
| Net income from continuing operations | 23.48%-17.48M | -37.36%-51.99M | ---12.44M | ---22.85M | ---37.85M |
| Depreciation and amortization | 650.00%15K | 90.00%19K | --14K | --2K | --10K |
| Other non cash items | -99.49%68K | --13.5M | --113K | --13.35M | ---- |
| Change In working capital | -18.89%-1.86M | -294.46%-9.62M | --2.94M | ---1.56M | --4.95M |
| -Change in prepaid assets | -532.00%-108K | 0.87%-914K | ---59K | --25K | ---922K |
| -Change in payables and accrued expense | -6.14%-1.68M | -247.56%-8.66M | --3.04M | ---1.58M | --5.87M |
| -Change in other current liabilities | -928.57%-72K | ---47K | ---40K | ---7K | --0 |
| Cash from discontinued investing activities | |||||
| Operating cash flow | -63.54%-17.22M | -42.25%-45.63M | ---8.04M | ---10.53M | ---32.08M |
| Investing cash flow | |||||
| Cash flow from continuing investing activities | 94.67%-8K | -205.21%-586K | -436K | -150K | -192K |
| Net PPE purchase and sale | 94.67%-8K | -205.21%-586K | ---436K | ---150K | ---192K |
| Cash from discontinued investing activities | |||||
| Investing cash flow | 94.67%-8K | -205.21%-586K | ---436K | ---150K | ---192K |
| Financing cash flow | |||||
| Cash flow from continuing financing activities | 737.39%334.14M | 759.74%272.5M | 194.7M | 39.9M | 31.7M |
| Net preferred stock issuance | --0 | 763.63%272.35M | --194.7M | --39.82M | --31.54M |
| Proceeds from stock option exercised by employees | -28.57%60K | -6.88%149K | --0 | --84K | --160K |
| Cash from discontinued financing activities | |||||
| Financing cash flow | 737.39%334.14M | 759.74%272.5M | --194.7M | --39.9M | --31.7M |
| Net cash flow | |||||
| Beginning cash position | 1,259.94%203.86M | -12.11%4.16M | --44.21M | --14.99M | --4.73M |
| Current changes in cash | 984.54%316.9M | 39,590.75%226.28M | --186.23M | --29.22M | ---573K |
| End cash Position | 1,077.92%520.76M | 5,442.09%230.44M | --230.44M | --44.21M | --4.16M |
| Free cash flow | -61.32%-17.23M | -43.22%-46.21M | ---8.47M | ---10.68M | ---32.27M |
| Currency Unit | USD | USD | USD | USD | USD |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
